KeyBanc Capital Markets maintained its Overweight rating and $274.00 price target on ResMed (NYSE: RMD) stock following industry observations. The target aligns with broader analyst expectations, with ...

According to InvestingPro data, ResMed currently trades near its 52-week high of $263.05, having delivered a 20.72% return over the past year.

ResMed is also doubling its US manufacturing footprint in June 2025. GLP-1 drugs remain a positive for now. ResMed gathered data on 1.4 million sleep apnea patients prescribed a GLP-1 drug. It found ...

Type: Auto | Features: Touchscreen, on/off button, advanced event detection | Weight: Not stated ResMed is one of the best-known CPAP machine brands, so it's no surprise that the AirSense 11 ...

We award ResMed a narrow moat rating based on switching costs and intangible assets, which have helped the company achieve high customer adherence rates and above-average industry growth. In ...

As the chorus trilled in the musical Oklahoma! – the farmer and the cowboy should be friends. In the case of Resmed, the developers of a new class of anti-obesity drugs look like being far more ...

ResMed Inc. (NYSE:RMD) Q2 2025 Earnings Call Transcript January 30, 2025 ResMed Inc. beats earnings expectations. Reported EPS is $2.43, expectations were $2.32. Operator: Welcome to the Q2 Fiscal ...

ResMed reported $1.28 billion in revenue for Q2 2025, a 10% increase year-over-year, aligning closely with analysts' revenue estimate of $1.27 billion. Non-GAAP EPS reached $2.42, surpassing the ...

Quarterly Highlights ResMed's 10.2% revenue jump in Q2 was driven by strong demand for sleep health products, with a particular focus on expansion in digital health platforms.